Order byBest matchMost fresh

Hims & Hers Stock Surges

Digest more
Top News
Impacts
The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.
From The Wall Street Journal
Hims & Hers expects at least $725 million in revenue from its weight-loss services alone in 2025.
From U.S. News & World Report

Read more on News Digest

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on se
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Why Hims & Hers Health Stock Soared Tuesday
Hims & Hers revealed Tuesday that it will begin offering branded versions of Eli Lilly's tirzepatide -- the active ingredient in weight loss
Modern Healthcare12h
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.
Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects.
Hims & Hers Zepbound Offering Won’t Bring Needed Sales Boom, Analysts Say
Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.
Explore more
Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty
Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims & Hers stock plunged more than 50% at one point. Is this once-high-flying healthcare stock a smart buy now?
Feedback